These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 16539696)

  • 1. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
    Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
    BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
    Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
    Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Odefrey F; Domènech M; Moncoutier V; Martínez-Ferrandis JI; Osorio A; Balmaña J; Barroso A; Armengod ME; Benítez J; Alonso C; Stoppa-Lyonnet D; Goldgar D; Baiget M
    Hum Mutat; 2003 Apr; 21(4):452. PubMed ID: 12655574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.
    Berman DB; Costalas J; Schultz DC; Grana G; Daly M; Godwin AK
    Cancer Res; 1996 Aug; 56(15):3409-14. PubMed ID: 8758903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.
    Infante M; Durán M; Acedo A; Pérez-Cabornero L; Sanz DJ; García-González M; Beristain E; Esteban-Cardeñosa E; de la Hoya M; Teulé A; Vega A; Tejada MI; Lastra E; Miner C; Velasco EA
    Clin Genet; 2010 Jan; 77(1):60-9. PubMed ID: 19912264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
    Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
    J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
    Cini G; Mezzavilla M; Della Puppa L; Cupelli E; Fornasin A; D'Elia AV; Dolcetti R; Damante G; Bertok S; Miolo G; Maestro R; de Paoli P; Amoroso A; Viel A
    BMC Med Genet; 2016 Feb; 17():11. PubMed ID: 26852130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations.
    Rudkin TM; Hamel N; Galvez M; Hogervorst F; Gille JJ; Møller P; Apold J; Foulkes WD
    BMC Med Genet; 2006 Mar; 7():15. PubMed ID: 16509964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations.
    Oros KK; Ghadirian P; Greenwood CM; Perret C; Shen Z; Paredes Y; Arcand SL; Mes-Masson AM; Narod SA; Foulkes WD; Provencher D; Tonin PN
    Int J Cancer; 2004 Nov; 112(3):411-9. PubMed ID: 15382066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
    Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Haplotype of the BRCA2 6857delAA mutation in 4 families with breast/ovarian cancer].
    Campos B; Díez O; Alvarez C; Palma L; Domènech M; Balmaña J; Sanz J; Ramírez A; Alonso C; Carvallo P; Baiget M
    Med Clin (Barc); 2004 Oct; 123(14):543-5. PubMed ID: 15535929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.
    Cavallone L; Arcand SL; Maugard C; Ghadirian P; Mes-Masson AM; Provencher D; Tonin PN
    BMC Cancer; 2008 Apr; 8():96. PubMed ID: 18402691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Origin and distribution of the BRCA2-8765delAG mutation in breast cancer.
    Palomba G; Cossu A; Friedman E; Budroni M; Farris A; Contu A; Pisano M; Baldinu P; Sini MC; Tanda F; Palmieri G
    BMC Cancer; 2007 Jul; 7():132. PubMed ID: 17640379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA2 founder mutation in Slovenian breast cancer families.
    Krajc M; De Grève J; Goelen G; Teugels E
    Eur J Hum Genet; 2002 Dec; 10(12):879-82. PubMed ID: 12461697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.